ArticleAbdominal radiology (New York)2026
MRI-derived visceral adipose tissue quantification enhances stratification of nonalcoholic steatohepatitis severity and fibrosis in obesity.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeVisceral adiposity is a key factor in the development of nonalcoholic steatohepatitis (NASH), yet its quantitative relationship with fibrotic progression remains inadequately characterized. This study aimed to assess the diagnostic performance of MRI-derived visceral fat content (VFC) for stratifying NASH severity and fibrosis in obese individuals.
methodsIn this retrospective, single-center study, 138 obese patients (body mass index ≥ 30 kg/m²) who underwent liver biopsy and chemical shift-encoded MRI (iterative decomposition of water and fat with echo asymmetry and least-squares estimation quantitation (IDEAL-IQ)) between April 2020 and September 2022 were included. Fibrotic NASH (Fibro-NASH) was defined histologically as a NAFLD activity score (NAS) ≥ 4 and fibrosis stage ≥ 2. MRI-derived metrics, including VFC and visceral fat area (VFA), were compared between groups. Multivariable logistic regression and receiver operating characteristic (ROC) analyses were performed.
resultsPatients with Fibro-NASH had significantly lower median VFC compared to those without Fibro-NASH (P < 0.001). VFC was identified as an independent predictor of Fibro-NASH (odds ratio (OR) = 0.51, 95% CI: 0.26-0.97). A model combining VFC, muscle fat content, and aspartate aminotransferase exhibited the highest predictive accuracy for Fibro-NASH (AUC = 0.89; 95% CI, 0.80-0.97), outperforming models using VFA and VFC alone (both P < 0.05).
conclusionMRI-derived VFC represents a promising, noninvasive biomarker for assessing NASH severity and its progression to Fibro-NASH in obesity. Integrating VFC into clinical practice may enhance risk stratification and facilitate timely interventions for advanced liver disease.
Indexed as
Identifiers
41801376What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.